High-throughput and affordable genome-wide methylation profiling of circulating cell-free DNA by methylated DNA sequencing (MeD-seq) of LpnPI digested fragments
Clin Epigenetics. 2021 Oct 20;13(1):196. doi: 10.1186/s13148-021-01177-4.ABSTRACTBACKGROUND: DNA methylation detection in liquid biopsies provides a highly promising and much needed means for real-time monitoring of disease load in advanced cancer patient care. Compared to the often-used somatic mutations, tissue- and cancer-type specific epigenetic marks affect a larger part of the cancer genome and generally have a high penetrance throughout the tumour. Here, we describe the successful application of the recently described MeD-seq assay for genome-wide DNA methylation profiling on cell-free DNA (cfDNA). The compatibility...
Source: Clinical Colorectal Cancer - October 21, 2021 Category: Cancer & Oncology Authors: Teoman Deger Ruben G Boers Vanja de Weerd Lindsay Angus Marjolijn M J van der Put Joachim B Boers Z Azmani Wilfred F J van IJcken Dirk J Gr ünhagen Lisanne F van Dessel Martijn P J K Lolkema Cornelis Verhoef Stefan Sleijfer John W M Martens Joost Gribnau Source Type: research

The Stage Migration Should be Reconsidered in Stage IIIA Rectal Cancer: Based on Propensity Score Analysis
CONCLUSION: Stage IIIA group showed similar survival outcomes compared to stage IIA and IIB group and significantly better outcomes than stage IIC group. Thus, it should be considered to classify stage IIIA as a subgroup of stage II rather than as a subgroup of stage III rectal cancer. It should be also be considered to change to determine whether to do adjuvant treatment according to stage II rectal cancer.PMID:34670724 | DOI:10.1016/j.clcc.2021.09.007 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 21, 2021 Category: Cancer & Oncology Authors: Jung Kyong Shin Hee Cheol Kim Woo Yong Lee Seong Hyeon Yun Yong Beom Cho Jung Wook Huh Yoon Ah Park Source Type: research

Expression of VEGF, EGF and HGF in early- and late-stage colorectal cancer
Mol Clin Oncol. 2021 Dec;15(6):251. doi: 10.3892/mco.2021.2413. Epub 2021 Oct 8.ABSTRACTThe heterogenous nature of colorectal cancer (CRC) highlights the need for a better understanding of the growth factors that affect tumour growth and cancer progression. The aim of the present study was to evaluate the role of epidermal growth factor (EGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in the early (I and II) and late (III and IV) stages of CRC. The serum levels and mRNA expression (n=30) of the aforementioned growth factors were measured and immunohistochemistry (n=20) was performed in pa...
Source: Clinical Colorectal Cancer - October 21, 2021 Category: Cancer & Oncology Authors: Maha-Hamadien Abdulla Asma Sultana Shaik Mansoor-Ali Vaali-Mohammed Khayal Abdulmalik Al Khayal Thamer Bin Traiki Ahmad Mohammed Zubaidi Tariq Al-Johani Zahid Shakoor Omar Abdullah Al-Obeed Source Type: research

Acute urinary retention and risk of cancer: population based Danish cohort study
CONCLUSIONS: Acute urinary retention might be a clinical marker for occult urogenital, colorectal, and neurological cancers. Occult cancer should possibly be considered in patients aged 50 years or older presenting with acute urinary retention and no obvious underlying cause.PMID:34666981 | DOI:10.1136/bmj.n2305 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 20, 2021 Category: Cancer & Oncology Authors: Maria Bisgaard Bengtsen D óra Körmendiné Farkas Michael Borre Henrik Toft S ørensen Mette N ørgaard Source Type: research

Inactivation of AMPK leads to attenuation of antigen presentation and immune evasion in lung adenocarcinoma
Conclusions:The results provide evidence that the immune evasion noted in LKB1 inactivated lung cancer is due to subsequent inactivation of AMPK and attenuation of antigen presentation.PMID:34667030 | DOI:10.1158/1078-0432.CCR-21-2049 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 20, 2021 Category: Cancer & Oncology Authors: Yajing Gao Pekka J P P äivinen Sushil Tripathi Eva Domenech-Moreno Iris Poh Ling P L Wong Kari Vaahtomeri Ashwini S Nagaraj Sarang S Talwelkar Marc Foretz Emmy W Verschuren Benoit Viollet Yan Yan Tomi P Makela Source Type: research

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies
J Exp Clin Cancer Res. 2021 Oct 18;40(1):328. doi: 10.1186/s13046-021-02130-2.ABSTRACTCetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC). Cetuximab can prolong survival by 8.2 months in RAS wild-type (WT) mCRC patients. Unfortunately, resistance to targeted therapy impairs clinical use and efficiency. The mechanisms of resistance refer to intrinsic and extrinsic alterations of tumours. Multiple therapeutic strategies have been investigated extensively to overcome resistance to anti-EGFR mAbs. The intrin...
Source: Clinical Colorectal Cancer - October 19, 2021 Category: Cancer & Oncology Authors: Jing Zhou Qing Ji Qi Li Source Type: research

Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience
CONCLUSION: Although no statistically significant differences have been found in TT or PFS, it would be more advisable to use BFIR scheme due to its better results in OS and toxicity profile.PMID:34664108 | DOI:10.1007/s00228-021-03235-5 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 19, 2021 Category: Cancer & Oncology Authors: Raquel Claramunt Garc ía Carmen Luc ía Muñoz Cid Andr és Sánchez Ruiz Juan Francisco Mar ín Pozo Source Type: research

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies
J Exp Clin Cancer Res. 2021 Oct 18;40(1):328. doi: 10.1186/s13046-021-02130-2.ABSTRACTCetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC). Cetuximab can prolong survival by 8.2 months in RAS wild-type (WT) mCRC patients. Unfortunately, resistance to targeted therapy impairs clinical use and efficiency. The mechanisms of resistance refer to intrinsic and extrinsic alterations of tumours. Multiple therapeutic strategies have been investigated extensively to overcome resistance to anti-EGFR mAbs. The intrin...
Source: Clinical Colorectal Cancer - October 19, 2021 Category: Cancer & Oncology Authors: Jing Zhou Qing Ji Qi Li Source Type: research

Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience
CONCLUSION: Although no statistically significant differences have been found in TT or PFS, it would be more advisable to use BFIR scheme due to its better results in OS and toxicity profile.PMID:34664108 | DOI:10.1007/s00228-021-03235-5 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 19, 2021 Category: Cancer & Oncology Authors: Raquel Claramunt Garc ía Carmen Luc ía Muñoz Cid Andr és Sánchez Ruiz Juan Francisco Mar ín Pozo Source Type: research

Systematic study on expression and prognosis of E2Fs in human colorectal cancer
CONCLUSIONS: E2Fs may be candidate biomarkers for CRC diagnosis and E2F3, 4 are potential prognosis biomarkers of CRC. Nevertheless, our findings must be validated in the future to popularize the clinical application of E2Fs in CRC.PMID:34661779 | DOI:10.1007/s10147-021-02051-2 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 18, 2021 Category: Cancer & Oncology Authors: Yating Ma Shijian Wang Jinfeng Bao Chengbin Wang Source Type: research

Impact of subcutaneous and visceral fat adiposity in patients with colorectal cancer
CONCLUSION: High SFA was correlated with better DFS in patients with CRC. Subcutaneous fat can have additive predictive capability when incorporated into clinical decision-making.PMID:34662848 | DOI:10.1016/j.clnu.2021.10.001 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 18, 2021 Category: Cancer & Oncology Authors: Jin-Mok Kim Eric Chung Eun-Suk Cho Jae-Hoon Lee Su-Jin Shin Hye Sun Lee Eun Jung Park Seung Hyuk Baik Kang Young Lee Jeonghyun Kang Source Type: research

Systematic study on expression and prognosis of E2Fs in human colorectal cancer
CONCLUSIONS: E2Fs may be candidate biomarkers for CRC diagnosis and E2F3, 4 are potential prognosis biomarkers of CRC. Nevertheless, our findings must be validated in the future to popularize the clinical application of E2Fs in CRC.PMID:34661779 | DOI:10.1007/s10147-021-02051-2 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 18, 2021 Category: Cancer & Oncology Authors: Yating Ma Shijian Wang Jinfeng Bao Chengbin Wang Source Type: research

The novel circSLC6A6/miR-1265/C2CD4A axis promotes colorectal cancer growth by suppressing p53 signaling pathway
CONCLUSION: Our results identified that circSLC6A6/miR-1265/C2CD4A axis, which was involved in CRC via the p53 signaling pathway, may serve as a therapeutic target for CRC.PMID:34656159 | DOI:10.1186/s13046-021-02126-y (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 17, 2021 Category: Cancer & Oncology Authors: Zeyin Rong Zai Luo Zhongmao Fu Pengshan Zhang Tengfei Li Jianming Zhang Zhonglin Zhu Zhilong Yu Qi Li Zhengjun Qiu Chen Huang Source Type: research

"Left in limbo": Exploring how patients with colorectal cancer interpret and respond to a suspected Lynch syndrome diagnosis
CONCLUSIONS: Our study findings highlight the variability in patients' interpretations of their diagnosis, cancer risk management and family communication when a diagnosis of SLS is received, and provide novel insights into how healthcare professionals can better support patients with SLS.PMID:34656160 | DOI:10.1186/s13053-021-00201-1 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 17, 2021 Category: Cancer & Oncology Authors: Nicole den Elzen Sharelle L Joseland Sibel Saya Sowmya Jonnagadla Joanne Isbister Ingrid Winship Daniel D Buchanan Source Type: research

Brain abscess and colorectal cancer
Med Clin (Barc). 2021 Oct 13:S0025-7753(21)00520-0. doi: 10.1016/j.medcli.2021.06.030. Online ahead of print.NO ABSTRACTPMID:34656341 | DOI:10.1016/j.medcli.2021.06.030 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 17, 2021 Category: Cancer & Oncology Authors: Teresa Pascual Vicente Arkaitz Perfecto Valero Jose Mar ía García Gonzalez Source Type: research

Concepts and prospects of minimally invasive colorectal cancer surgery
This article outlines the history, current concepts, evolving techniques, and future prospects of MIS as it pertains to colorectal cancer surgery.PMID:34654544 | DOI:10.1016/j.crad.2021.09.013 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 16, 2021 Category: Cancer & Oncology Authors: J Merchant D McArthur H Ferguson S Ramcharan Source Type: research

Concepts and prospects of minimally invasive colorectal cancer surgery
This article outlines the history, current concepts, evolving techniques, and future prospects of MIS as it pertains to colorectal cancer surgery.PMID:34654544 | DOI:10.1016/j.crad.2021.09.013 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 16, 2021 Category: Cancer & Oncology Authors: J Merchant D McArthur H Ferguson S Ramcharan Source Type: research

Thymidylate synthase locus LOH in combination with genotype has prognostic and predictive significance in colorectal cancer
In conclusion, LOH status should be considered when TS genotype is explored as a potential prognostic and predictive marker for 5-FU-based adjuvant chemotherapy in colorectal cancer.PMID:34650802 | PMC:PMC8506693 | DOI:10.3892/mco.2021.2398 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 15, 2021 Category: Cancer & Oncology Authors: Masanori Kotake Hiroyuki Bando Mami Kaneko Hirofumi Takemura Toshinari Minamoto Kazuyuki Kawakami Source Type: research

Identification of serum anti-striatin 4 antibodies as a common marker for esophageal cancer and other solid cancers
Mol Clin Oncol. 2021 Nov;15(5):237. doi: 10.3892/mco.2021.2399. Epub 2021 Sep 20.ABSTRACTSolid cancers have a poor prognosis, and their morbidity and mortality after surgery is high. Even after radical surgery for esophageal cancer, there have been cases of early postoperative death. The present study therefore aimed to explore new tumor markers that can predict the early postoperative prognosis. To identify antibody markers, serological antigens were identified using recombinant cDNA expression cloning (SEREX). The results identified striatin 4 (STRN4) as the antigen recognized by serum IgG antibodies in patients with eso...
Source: Clinical Colorectal Cancer - October 15, 2021 Category: Cancer & Oncology Authors: Masaaki Ito Takaki Hiwasa Yoko Oshima Satoshi Yajima Takashi Suzuki Tatsuki Nanami Makoto Sumazaki Fumiaki Shiratori Kimihiko Funahashi Hirotaka Takizawa Koichi Kashiwado Naobumi Tochigi Hideaki Shimada Source Type: research

Scatter patterns in lymph node metastases as a novel prognostic indicator in patients with stage III/N2 colorectal cancer
Mol Clin Oncol. 2021 Nov;15(5):239. doi: 10.3892/mco.2021.2402. Epub 2021 Sep 21.ABSTRACTTo classify patients with stage III/N2 colorectal cancer into high- and low-risk groups for recurrence, the present study compared clinicopathological features by immunohistochemical staining. The single-center analysis included 53/668 patients (7.9%) with stage III/N2 colorectal cancer who underwent radical resection between January 2006 and December 2014. The present study examined cancer cell distribution in metastatic lymph nodes and classified patients into a group with circumferential localization patterns like a cystic mass (CLP...
Source: Clinical Colorectal Cancer - October 15, 2021 Category: Cancer & Oncology Authors: Takuya Koike Masaya Mukai Shinichiro Hiraiwa Kyoko Kishima Daiki Yokoyama Shuji Uda Sayuri Hasegawa Takayuki Tajima Eiji Nomura Tomoko Sugiyama Takuma Tajiri Source Type: research

Complete response of MSI-high metastatic colon cancer following treatment with regorafenib: A case report
Mol Clin Oncol. 2021 Nov;15(5):243. doi: 10.3892/mco.2021.2405. Epub 2021 Sep 24.ABSTRACTRegorafenib has been demonstrated to prolong survival in patients with metastatic colorectal cancer refractory to standard chemotherapy. However, overall survival is limited to 2.5 months. The present report describes a unique case of metastatic colon cancer, which showed a complete response to regorafenib. A 54-year-old woman was diagnosed with right colon cancer obstruction with peritoneal seeding. The patient underwent laparoscopic right hemicolectomy, and the pathology was T4aN2bM1, moderately differentiated adenocarcinoma with hig...
Source: Clinical Colorectal Cancer - October 15, 2021 Category: Cancer & Oncology Authors: Hyungjoo Baik Hee Ju Lee Jueun Park Ha Young Park Jinyoung Park Sunseong Lee Ki Beom Bae Source Type: research

Impact of Expanding Screening Colonoscopy Interval on Providers Choice of Prescribing Colonoscopy for Colorectal Cancer Screening
CONCLUSIONS: Expanding colonoscopy screening interval to 15 years could produce an increase in physicians and nurse practitioners choice of using colonoscopy for CRC screening, but the clinical impact appears minor. Additional surveys of patients and providers are needed.PMID:34653063 | DOI:10.1097/MCG.0000000000001628 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 15, 2021 Category: Cancer & Oncology Authors: Douglas K Rex Rachel E Lahr Daniel A Handel Kevin B Gebke Krishna C Vemulapalli Source Type: research

Corrigendum to: "Fasting Plasma Glucose and Incident Colorectal Cancer: Analysis of a Nationwide Epidemiological Database"
J Clin Endocrinol Metab. 2021 Oct 15:dgab733. doi: 10.1210/clinem/dgab733. Online ahead of print.NO ABSTRACTPMID:34653255 | DOI:10.1210/clinem/dgab733 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 15, 2021 Category: Cancer & Oncology Source Type: research

Letter to the editor: Correction "Nitrate-nitrite exposure through drinking water and diet and risk of colorectal cancer: A systematic review and meta-analysis of observational studies"
Clin Nutr. 2021 Sep 21;40(11):5443-5444. doi: 10.1016/j.clnu.2021.09.027. Online ahead of print.NO ABSTRACTPMID:34653823 | DOI:10.1016/j.clnu.2021.09.027 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 15, 2021 Category: Cancer & Oncology Authors: Tim Chambers Simon Hales Andrew Anglemyer Source Type: research

Thymidylate synthase locus LOH in combination with genotype has prognostic and predictive significance in colorectal cancer
In conclusion, LOH status should be considered when TS genotype is explored as a potential prognostic and predictive marker for 5-FU-based adjuvant chemotherapy in colorectal cancer.PMID:34650802 | PMC:PMC8506693 | DOI:10.3892/mco.2021.2398 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 15, 2021 Category: Cancer & Oncology Authors: Masanori Kotake Hiroyuki Bando Mami Kaneko Hirofumi Takemura Toshinari Minamoto Kazuyuki Kawakami Source Type: research

Identification of serum anti-striatin 4 antibodies as a common marker for esophageal cancer and other solid cancers
Mol Clin Oncol. 2021 Nov;15(5):237. doi: 10.3892/mco.2021.2399. Epub 2021 Sep 20.ABSTRACTSolid cancers have a poor prognosis, and their morbidity and mortality after surgery is high. Even after radical surgery for esophageal cancer, there have been cases of early postoperative death. The present study therefore aimed to explore new tumor markers that can predict the early postoperative prognosis. To identify antibody markers, serological antigens were identified using recombinant cDNA expression cloning (SEREX). The results identified striatin 4 (STRN4) as the antigen recognized by serum IgG antibodies in patients with eso...
Source: Clinical Colorectal Cancer - October 15, 2021 Category: Cancer & Oncology Authors: Masaaki Ito Takaki Hiwasa Yoko Oshima Satoshi Yajima Takashi Suzuki Tatsuki Nanami Makoto Sumazaki Fumiaki Shiratori Kimihiko Funahashi Hirotaka Takizawa Koichi Kashiwado Naobumi Tochigi Hideaki Shimada Source Type: research

Scatter patterns in lymph node metastases as a novel prognostic indicator in patients with stage III/N2 colorectal cancer
Mol Clin Oncol. 2021 Nov;15(5):239. doi: 10.3892/mco.2021.2402. Epub 2021 Sep 21.ABSTRACTTo classify patients with stage III/N2 colorectal cancer into high- and low-risk groups for recurrence, the present study compared clinicopathological features by immunohistochemical staining. The single-center analysis included 53/668 patients (7.9%) with stage III/N2 colorectal cancer who underwent radical resection between January 2006 and December 2014. The present study examined cancer cell distribution in metastatic lymph nodes and classified patients into a group with circumferential localization patterns like a cystic mass (CLP...
Source: Clinical Colorectal Cancer - October 15, 2021 Category: Cancer & Oncology Authors: Takuya Koike Masaya Mukai Shinichiro Hiraiwa Kyoko Kishima Daiki Yokoyama Shuji Uda Sayuri Hasegawa Takayuki Tajima Eiji Nomura Tomoko Sugiyama Takuma Tajiri Source Type: research

Complete response of MSI-high metastatic colon cancer following treatment with regorafenib: A case report
Mol Clin Oncol. 2021 Nov;15(5):243. doi: 10.3892/mco.2021.2405. Epub 2021 Sep 24.ABSTRACTRegorafenib has been demonstrated to prolong survival in patients with metastatic colorectal cancer refractory to standard chemotherapy. However, overall survival is limited to 2.5 months. The present report describes a unique case of metastatic colon cancer, which showed a complete response to regorafenib. A 54-year-old woman was diagnosed with right colon cancer obstruction with peritoneal seeding. The patient underwent laparoscopic right hemicolectomy, and the pathology was T4aN2bM1, moderately differentiated adenocarcinoma with hig...
Source: Clinical Colorectal Cancer - October 15, 2021 Category: Cancer & Oncology Authors: Hyungjoo Baik Hee Ju Lee Jueun Park Ha Young Park Jinyoung Park Sunseong Lee Ki Beom Bae Source Type: research

Impact of Expanding Screening Colonoscopy Interval on Providers Choice of Prescribing Colonoscopy for Colorectal Cancer Screening
CONCLUSIONS: Expanding colonoscopy screening interval to 15 years could produce an increase in physicians and nurse practitioners choice of using colonoscopy for CRC screening, but the clinical impact appears minor. Additional surveys of patients and providers are needed.PMID:34653063 | DOI:10.1097/MCG.0000000000001628 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 15, 2021 Category: Cancer & Oncology Authors: Douglas K Rex Rachel E Lahr Daniel A Handel Kevin B Gebke Krishna C Vemulapalli Source Type: research

Corrigendum to: "Fasting Plasma Glucose and Incident Colorectal Cancer: Analysis of a Nationwide Epidemiological Database"
J Clin Endocrinol Metab. 2021 Oct 15:dgab733. doi: 10.1210/clinem/dgab733. Online ahead of print.NO ABSTRACTPMID:34653255 | DOI:10.1210/clinem/dgab733 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 15, 2021 Category: Cancer & Oncology Source Type: research

Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer
Clin Colorectal Cancer. 2021 Sep 15:S1533-0028(21)00092-X. doi: 10.1016/j.clcc.2021.09.006. Online ahead of print.ABSTRACTAnal cancer is a relatively rare, mostly HPV-related cancer. The curative treatment consists of concurrent chemoradiation delivered with modern radiotherapy techniques. The prognosis for most patients with early localized disease is very favourable; however patients with locally advanced disease and/or HPV negative tumours are at higher risk of locoregional and distant treatment failure. Tailored approaches are presently being investigated to determine the most suitable regimen in terms of radiotherapy ...
Source: Clinical Colorectal Cancer - October 14, 2021 Category: Cancer & Oncology Authors: Marianne Gr ønlie Guren David Sebag-Montefiore Pierfrancesco Franco Anders Johnsson Eva Segelov Eric Deutsch Sheela Rao Karen-Lise Garm Spindler Dirk Arnold Source Type: research

Standard-Dose Trifluridine/Tipiracil as Safe Treatment Alternative in Metastatic Colorectal Cancer Patients With DPD Deficiency
Clin Colorectal Cancer. 2021 Sep 15:S1533-0028(21)00090-6. doi: 10.1016/j.clcc.2021.09.004. Online ahead of print.NO ABSTRACTPMID:34645590 | DOI:10.1016/j.clcc.2021.09.004 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 14, 2021 Category: Cancer & Oncology Authors: Jeroen F Schouten Jeroen Willems Stefan J W J Sanders Geert-Jan Creemers Maarten J Deenen Source Type: research

Phase Ib/II study of Cetuximab Plus Pembrolizumab in Patients with Advanced RAS wild-type Colorectal Cancer
Clin Cancer Res. 2021 Oct 13:clincanres.1650.2021. doi: 10.1158/1078-0432.CCR-21-1650. Online ahead of print.ABSTRACTPURPOSE: We evaluated the antitumor efficacy of cetuximab in combination with pembrolizumab in patients with RAS wild-type (RASwt), metastatic colorectal adenocarcinoma (mCRC).EXPERIMENTAL DESIGN: In this phase Ib/II study, cetuximab was combined with pembrolizumab in patients with RASwt mCRC with {greater than or equal to} one prior line of therapy for advanced disease. We analyzed baseline on-treatment tumor tissues for changes in the tumor microenvironment (TME), using flow cytometry and multispectral imm...
Source: Clinical Colorectal Cancer - October 14, 2021 Category: Cancer & Oncology Authors: Christos Fountzilas David L Bajor Sarbajit Mukherjee Joel Saltzman Agnieszka K Witkiewicz Orla Maguire Hans Minderman Ram Nambiar Hanna R Rosenheck Erik S Knudsen Jason B Muhitch Scott I Abrams Chong Wang Alan D Hutson Kristopher Attwood Karen A Hicks Jen Source Type: research

Improving the management of early colorectal cancers (eCRC) by using quantitative markers to predict lymph node involvement and thus the need for major resection of pT1 cancers
CONCLUSIONS: In this study, we were able to reduce the potential resection rate of pT1 with the multivariate qualitative and/or quantitative model to 34% or 35% while detecting 95% or 90% of all LNM cases, respectively. While these findings need to be validated, this model could lead to a reduction of the major resection rate in eCRC.PMID:34645701 | DOI:10.1136/jclinpath-2021-207482 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 14, 2021 Category: Cancer & Oncology Authors: Scarlet Brockmoeller Eu-Wing Toh Katerina Kouvidi Sarah Hepworth Eva Morris Philip Quirke Source Type: research

Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer
Clin Colorectal Cancer. 2021 Sep 15:S1533-0028(21)00092-X. doi: 10.1016/j.clcc.2021.09.006. Online ahead of print.ABSTRACTAnal cancer is a relatively rare, mostly HPV-related cancer. The curative treatment consists of concurrent chemoradiation delivered with modern radiotherapy techniques. The prognosis for most patients with early localized disease is very favourable; however patients with locally advanced disease and/or HPV negative tumours are at higher risk of locoregional and distant treatment failure. Tailored approaches are presently being investigated to determine the most suitable regimen in terms of radiotherapy ...
Source: Clinical Colorectal Cancer - October 14, 2021 Category: Cancer & Oncology Authors: Marianne Gr ønlie Guren David Sebag-Montefiore Pierfrancesco Franco Anders Johnsson Eva Segelov Eric Deutsch Sheela Rao Karen-Lise Garm Spindler Dirk Arnold Source Type: research

Standard-Dose Trifluridine/Tipiracil as Safe Treatment Alternative in Metastatic Colorectal Cancer Patients With DPD Deficiency
Clin Colorectal Cancer. 2021 Sep 15:S1533-0028(21)00090-6. doi: 10.1016/j.clcc.2021.09.004. Online ahead of print.NO ABSTRACTPMID:34645590 | DOI:10.1016/j.clcc.2021.09.004 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 14, 2021 Category: Cancer & Oncology Authors: Jeroen F Schouten Jeroen Willems Stefan J W J Sanders Geert-Jan Creemers Maarten J Deenen Source Type: research

Phase Ib/II study of Cetuximab Plus Pembrolizumab in Patients with Advanced RAS wild-type Colorectal Cancer
Clin Cancer Res. 2021 Oct 13:clincanres.1650.2021. doi: 10.1158/1078-0432.CCR-21-1650. Online ahead of print.ABSTRACTPURPOSE: We evaluated the antitumor efficacy of cetuximab in combination with pembrolizumab in patients with RAS wild-type (RASwt), metastatic colorectal adenocarcinoma (mCRC).EXPERIMENTAL DESIGN: In this phase Ib/II study, cetuximab was combined with pembrolizumab in patients with RASwt mCRC with {greater than or equal to} one prior line of therapy for advanced disease. We analyzed baseline on-treatment tumor tissues for changes in the tumor microenvironment (TME), using flow cytometry and multispectral imm...
Source: Clinical Colorectal Cancer - October 14, 2021 Category: Cancer & Oncology Authors: Christos Fountzilas David L Bajor Sarbajit Mukherjee Joel Saltzman Agnieszka K Witkiewicz Orla Maguire Hans Minderman Ram Nambiar Hanna R Rosenheck Erik S Knudsen Jason B Muhitch Scott I Abrams Chong Wang Alan D Hutson Kristopher Attwood Karen A Hicks Jen Source Type: research

Improving the management of early colorectal cancers (eCRC) by using quantitative markers to predict lymph node involvement and thus the need for major resection of pT1 cancers
CONCLUSIONS: In this study, we were able to reduce the potential resection rate of pT1 with the multivariate qualitative and/or quantitative model to 34% or 35% while detecting 95% or 90% of all LNM cases, respectively. While these findings need to be validated, this model could lead to a reduction of the major resection rate in eCRC.PMID:34645701 | DOI:10.1136/jclinpath-2021-207482 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 14, 2021 Category: Cancer & Oncology Authors: Scarlet Brockmoeller Eu-Wing Toh Katerina Kouvidi Sarah Hepworth Eva Morris Philip Quirke Source Type: research

Evaluation of a Targeted Next-Generation Sequencing Panel for the Non-Invasive Detection of Variants in Circulating DNA of Colorectal Cancer
J Clin Med. 2021 Sep 29;10(19):4487. doi: 10.3390/jcm10194487.ABSTRACTMolecular profiling of circulating cell-free DNA (cfDNA) has shown utility for the management of colorectal cancer (CRC). TruSight Tumor 170 (TST170) is a next-generation sequencing (NGS) panel that covers 170 cancer-related genes, including KRAS, which is a key driver gene in CRC. We evaluated the capacity of TST170 to detect gene variants in cfDNA from a retrospective cohort of 20 metastatic CRC patients with known KRAS variants in tumor tissue and in cfDNA previously analyzed by pyrosequencing and BEAMing, respectively. The cfDNA of most of the patien...
Source: Clinical Colorectal Cancer - October 13, 2021 Category: Cancer & Oncology Authors: Aitor Rodr íguez-Casanova Aida Bao-Caamano Ram ón M Lago-Lestón Elena Brozos-V ázquez Nicol ás Costa-Fraga Isabel Ferreir ós-Vidal Ihab Abdulkader Yolanda Vidal-Insua Francisca V ázquez Rivera Sonia Candamio Folgar Rafael L ópez-López Laura Muine Source Type: research

Health and life insurance-related problems in very long-term cancer survivors in Germany: a population-based study
CONCLUSION: Most cancer survivors did not change their HI nor tried to buy LI after cancer diagnosis. Problems with changing statutory HI were generally resolved with additional contribution while the main problem encountered when buying LI was rejection of request.PMID:34642793 | DOI:10.1007/s00432-021-03825-x (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 13, 2021 Category: Cancer & Oncology Authors: Melissa S Y Thong Daniela Doege Linda Wei ßer Lena Koch-Gallenkamp Heike Bertram Andrea Eberle Bernd Holleczek Alice Nennecke Annika Waldmann Sylke Ruth Zeissig Ron Pritzkuleit Michael Schlander Hermann Brenner Volker Arndt Source Type: research

The TRIM proteins in cancer: from expression to emerging regulatory mechanisms
Clin Transl Oncol. 2021 Oct 13. doi: 10.1007/s12094-021-02715-5. Online ahead of print.ABSTRACTNew clinical evidence suggests that dysregulation of the ubiquitin-mediated destruction of tumor suppressors or oncogene products is probably engaged in the etiology of leukemia and carcinoma. The superfamily of tripartite motif (TRIM)-containing protein family is among the biggest recognized single protein RING finger E3 ubiquitin ligases that are considered vital carcinogenesis regulators, which is not shocking since TRIM proteins are engaged in various biological processes, including cell growth, development, and differentiati...
Source: Clinical Colorectal Cancer - October 13, 2021 Category: Cancer & Oncology Authors: A Mohammadi M S Pour Abbasi S Khorrami S Khodamoradi Z Mohammadi Goldar F Ebrahimzadeh Source Type: research

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
CONCLUSION: Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC. Based on these promising data, randomized studies are warranted.PMID:34637336 | DOI:10.1200/JCO.21.01015 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 12, 2021 Category: Cancer & Oncology Authors: Heinz-Josef Lenz Eric Van Cutsem Maria Luisa Limon Ka Yeung Mark Wong Alain Hendlisz Massimo Aglietta Pilar Garc ía-Alfonso Bart Neyns Gabriele Luppi Dana B Cardin Tomislav Dragovich Usman Shah Sandzhar Abdullaev Joseph Gricar Jean-Marie Ledeine Michael Source Type: research

Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report
Clin Colorectal Cancer. 2021 Sep 15:S1533-0028(21)00088-8. doi: 10.1016/j.clcc.2021.09.002. Online ahead of print.NO ABSTRACTPMID:34629317 | DOI:10.1016/j.clcc.2021.09.002 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 11, 2021 Category: Cancer & Oncology Authors: Maria Alessandra Calegari Brunella Di Stefano Michele Basso Carmine Carbone Floriana Camarda Marta Ribelli Annunziato Anghelone Raffaella Vivolo Maria Bensi Maurizio Martini Carmelo Pozzo Maria Vellone Francesco Ardito Lisa Salvatore Felice Giuliante Giam Source Type: research

Utility of exome sequencing in routine care for metastatic colorectal cancer
In conclusion, this study highlighted that structural and pathway genomic features are associated with sidedness, synchronous status, RAS status and overall survival and could be helpful to improve the stratification of patients with colorectal cancer.PMID:34631054 | PMC:PMC8461624 | DOI:10.3892/mco.2021.2392 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 11, 2021 Category: Cancer & Oncology Authors: Melchior De Giraud D'Agay Lo ïck Galland Zoe Tharin Caroline Truntzer Francois Ghiringhelli Source Type: research

Metastatic disease to the liver: Locoregional therapy strategies and outcomes
World J Clin Oncol. 2021 Sep 24;12(9):725-745. doi: 10.5306/wjco.v12.i9.725.ABSTRACTSecondary cancers of the liver are more than twenty times more common than primary tumors and are incurable in most cases. While surgical resection and systemic chemotherapy are often the first-line therapy for metastatic liver disease, a majority of patients present with bilobar disease not amenable to curative local resection. Furthermore, by the time metastasis to the liver has developed, many tumors demonstrate a degree of resistance to systemic chemotherapy. Fortunately, catheter-directed and percutaneous locoregional approaches have e...
Source: Clinical Colorectal Cancer - October 11, 2021 Category: Cancer & Oncology Authors: Kylie E Zane Jordan M Cloyd Khalid S Mumtaz Vibhor Wadhwa Mina S Makary Source Type: research

Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report
Clin Colorectal Cancer. 2021 Sep 15:S1533-0028(21)00088-8. doi: 10.1016/j.clcc.2021.09.002. Online ahead of print.NO ABSTRACTPMID:34629317 | DOI:10.1016/j.clcc.2021.09.002 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 11, 2021 Category: Cancer & Oncology Authors: Maria Alessandra Calegari Brunella Di Stefano Michele Basso Carmine Carbone Floriana Camarda Marta Ribelli Annunziato Anghelone Raffaella Vivolo Maria Bensi Maurizio Martini Carmelo Pozzo Maria Vellone Francesco Ardito Lisa Salvatore Felice Giuliante Giam Source Type: research

Utility of exome sequencing in routine care for metastatic colorectal cancer
In conclusion, this study highlighted that structural and pathway genomic features are associated with sidedness, synchronous status, RAS status and overall survival and could be helpful to improve the stratification of patients with colorectal cancer.PMID:34631054 | PMC:PMC8461624 | DOI:10.3892/mco.2021.2392 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 11, 2021 Category: Cancer & Oncology Authors: Melchior De Giraud D'Agay Lo ïck Galland Zoe Tharin Caroline Truntzer Francois Ghiringhelli Source Type: research

Metastatic disease to the liver: Locoregional therapy strategies and outcomes
World J Clin Oncol. 2021 Sep 24;12(9):725-745. doi: 10.5306/wjco.v12.i9.725.ABSTRACTSecondary cancers of the liver are more than twenty times more common than primary tumors and are incurable in most cases. While surgical resection and systemic chemotherapy are often the first-line therapy for metastatic liver disease, a majority of patients present with bilobar disease not amenable to curative local resection. Furthermore, by the time metastasis to the liver has developed, many tumors demonstrate a degree of resistance to systemic chemotherapy. Fortunately, catheter-directed and percutaneous locoregional approaches have e...
Source: Clinical Colorectal Cancer - October 11, 2021 Category: Cancer & Oncology Authors: Kylie E Zane Jordan M Cloyd Khalid S Mumtaz Vibhor Wadhwa Mina S Makary Source Type: research

Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report
Clin Colorectal Cancer. 2021 Sep 15:S1533-0028(21)00088-8. doi: 10.1016/j.clcc.2021.09.002. Online ahead of print.NO ABSTRACTPMID:34629317 | DOI:10.1016/j.clcc.2021.09.002 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 11, 2021 Category: Cancer & Oncology Authors: Maria Alessandra Calegari Brunella Di Stefano Michele Basso Carmine Carbone Floriana Camarda Marta Ribelli Annunziato Anghelone Raffaella Vivolo Maria Bensi Maurizio Martini Carmelo Pozzo Maria Vellone Francesco Ardito Lisa Salvatore Felice Giuliante Giam Source Type: research

Utility of exome sequencing in routine care for metastatic colorectal cancer
In conclusion, this study highlighted that structural and pathway genomic features are associated with sidedness, synchronous status, RAS status and overall survival and could be helpful to improve the stratification of patients with colorectal cancer.PMID:34631054 | PMC:PMC8461624 | DOI:10.3892/mco.2021.2392 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - October 11, 2021 Category: Cancer & Oncology Authors: Melchior De Giraud D'Agay Lo ïck Galland Zoe Tharin Caroline Truntzer Francois Ghiringhelli Source Type: research